Lexaria Bioscience - LEXX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 278.01%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.91
▲ +0.12 (4.30%)

This chart shows the closing price for LEXX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lexaria Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LEXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LEXX

Analyst Price Target is $11.00
▲ +278.01% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lexaria Bioscience in the last 3 months. The average price target is $11.00, with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 278.01% upside from the last price of $2.91.

This chart shows the closing price for LEXX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Lexaria Bioscience. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/10/2024HC WainwrightInitiated CoverageBuy$10.00Low
3/5/2024Maxim GroupBoost TargetBuy ➝ Buy$3.00 ➝ $12.00Low
7/21/2023Maxim GroupInitiated CoverageBuy$2.00Low
(Data available from 7/16/2019 forward)

News Sentiment Rating

-0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/19/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/18/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/17/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Lexaria Bioscience logo
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Read More

Today's Range

Now: $2.91
Low: $2.70
High: $2.95

50 Day Range

MA: $3.09
Low: $2.58
High: $4.00

52 Week Range

Now: $2.91
Low: $0.72
High: $6.85

Volume

87,222 shs

Average Volume

336,151 shs

Market Capitalization

$37.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Lexaria Bioscience?

The following equities research analysts have issued stock ratings on Lexaria Bioscience in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for LEXX.

What is the current price target for Lexaria Bioscience?

2 Wall Street analysts have set twelve-month price targets for Lexaria Bioscience in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 278.0%. Maxim Group has the highest price target set, predicting LEXX will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Lexaria Bioscience in the next year.
View the latest price targets for LEXX.

What is the current consensus analyst rating for Lexaria Bioscience?

Lexaria Bioscience currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LEXX will outperform the market and that investors should add to their positions of Lexaria Bioscience.
View the latest ratings for LEXX.

What other companies compete with Lexaria Bioscience?

How do I contact Lexaria Bioscience's investor relations team?

Lexaria Bioscience's physical mailing address is 100 - 740 MCCURDY ROAD, KELOWNA A1, V1X 2P7. The company's listed phone number is (250) 765-6424 and its investor relations email address is [email protected]. The official website for Lexaria Bioscience is www.lexariabioscience.com. Learn More about contacing Lexaria Bioscience investor relations.